Total-Body Irradiation Followed By Cyclosporine and Mycophenolate Mofetil in Treating Patients With Severe Combined Immunodeficiency Undergoing Donor Bone Marrow Transplant

Severe Combined Immunodeficiency Clinical Trial

Official title:
Induction of Mixed Hematopoietic Chimerism in Patients With Severe Combined Immunodeficiency Disorders Using Allogeneic Bone Marrow and Post-Transplant Immunosuppression With Cyclosporine and Mycophenolate Mofetil

Status Completed

Clinical Trial Summary

This pilot clinical trial studies total-body irradiation followed by cyclosporine and mycophenolate mofetil in treating patients with severe combined immunodeficiency (SCID) undergoing donor bone marrow transplant. Giving total-body irradiation (TBI) before a donor bone marrow transplant using stem cells that closely match the patient's stem cells, helps stop the growth of abnormal cells. It may also stop the patient's immune system from rejecting the donor's stem cells. The donated stem cells may mix with the patient's immune cells and help destroy any remaining abnormal cells. Sometimes the transplanted cells from a donor can also make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after the transplant may stop this from happening.

Clinical Trial Description

PRIMARY OBJECTIVES:

I. To safely establish partial lymphoid chimerism (1-95% donor cluster of differentiation [CD]3+ cells) using a non-lethal conditioning regimen in patients with severe combined immunodeficiency syndrome.

II. To define the kinetics of immune reconstitution following a non-lethal conditioning regimen in patients with immunodeficiency diseases.

OUTLINE:

Patients receive cyclosporine orally (PO) or intravenously (IV) on days -3 to 100 followed by a taper until day 180 and mycophenolate mofetil PO or IV on days 0-40 with a taper until day 96 in the absence of unacceptable toxicity. Unrelated donor recipients also undergo TBI on day 0. Patients undergo bone marrow transplant on day 0.

After completion of study treatment, patients are followed up at 6 months and then yearly for 5 years. ;

Study Design

Related Conditions & MeSH terms

Adenosine Deaminase Deficiency
Agammaglobulinemia
Autosomal Recessive Disorder
Disease
Immune System Diseases
Immune System Disorder
Immunologic Deficiency Syndromes
Purine-Nucleoside Phosphorylase Deficiency
Severe Combined Immunodeficiency
Severe Combined Immunodeficiency With Absence of T and B Cells
X-Linked Combined Immunodeficiency Diseases
X-Linked Severe Combined Immunodeficiency

Clinical Trial Details

NCT number	NCT00008450
Study type	Interventional
Source	Fred Hutchinson Cancer Research Center
Contact
Status	Completed
Phase	Phase 1
Start date	August 11, 1997
Completion date	December 26, 2018

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00006335` - Influences on Female Adolescents' Decisions Regarding Testing for Carrier Status of XSCID	N/A
Not yet recruiting	`NCT02231983` - Clinical Characteristics and Genetic Profiles of Severe Combined Immunodeficiency in China	N/A
Active, not recruiting	`NCT03597594` - Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)	Phase 1/Phase 2
Completed	`NCT00000603` - Cord Blood Stem Cell Transplantation Study (COBLT)	Phase 2
Completed	`NCT00001255` - Gene Transfer Therapy for Severe Combined Immunodeficieny Disease (SCID) Due to Adenosine Deaminase (ADA) Deficiency: A Natural History Study	N/A
Recruiting	`NCT05651113` - The Experience of Screening for SCID
Completed	`NCT00794508` - MND-ADA Transduction of CD34+ Cells From Children With ADA-SCID	Phase 2
Recruiting	`NCT03538899` - Autologous Gene Therapy for Artemis-Deficient SCID	Phase 1/Phase 2
Recruiting	`NCT05298930` - Feasibility Study to Assess an Adapted Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Transplantation	N/A
Recruiting	`NCT01821781` - Immune Disorder HSCT Protocol	Phase 2
Completed	`NCT00845416` - Newborn Screening for Severe Combined Immunodeficiency (SCID) in a High-Risk Population	N/A
Terminated	`NCT00006054` - Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies	N/A
Completed	`NCT03878069` - Registry Study of Revcovi Treatment in Patients With ADA-SCID
Recruiting	`NCT01019876` - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases	Phase 2/Phase 3
Completed	`NCT03513328` - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation	Phase 1/Phase 2
Withdrawn	`NCT02177760` - Sirolimus Prophylaxis for aGVHD in TME SCID	Phase 2
Recruiting	`NCT00695279` - Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked Products
Completed	`NCT01420627` - EZN-2279 in Patients With ADA-SCID	Phase 3
Terminated	`NCT02127892` - SCID Bu/Flu/ATG Study With T Cell Depletion	Phase 1/Phase 2
Completed	`NCT04246840` - Study Through Imaging of Visceral Lymphoid Organs in Patients With SCID Who Have Recieved Bone Marrow Allograft

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.